tocainidum treatment
妥卡尼德治疗
tocainidum therapy
妥卡尼德疗法
tocainidum dosage
妥卡尼德剂量
tocainidum administration
妥卡尼德给药
tocainidum effects
妥卡尼德效果
taking tocainidum
服用妥卡尼德
tocainidum prescription
妥卡尼德处方
tocainidum medication
妥卡尼德药物
tocainidum regimen
妥卡尼德方案
administering tocainidum
使用妥卡尼德
the primary indication for tocainidum is the management of symptomatic ventricular arrhythmias.
盐酸妥卡尼的主要适应症是治疗症状性室性心律失常。
unlike lidocaine, tocainidum can be administered orally for chronic outpatient treatment.
与利多卡因不同，妥卡尼可以口服用于慢性门诊治疗。
physicians rarely prescribe tocainidum due to the potential for severe pulmonary toxicity.
由于可能导致严重的肺毒性，医生很少开具妥卡尼处方。
researchers observed a significant reduction in premature ventricular contractions using tocainidum.
研究人员观察到使用妥卡尼后室性期前收缩显著减少。
patients with bone marrow suppression should avoid using tocainidum if possible.
患有骨髓抑制的患者应尽可能避免使用妥卡尼。
common side effects associated with tocainidum include dizziness, nausea, and tremors.
与妥卡尼���关的常见副作用包括头晕、恶心和震颤。
plasma concentration monitoring is essential to optimize the therapeutic dose of tocainidum.
监测血浆浓度对于优化妥卡尼的治疗剂量至关重要。
tocainidum is a class ib antiarrhythmic agent chemically related to lidocaine.
妥卡尼是一种ib类抗心律失常药，化学结构与利多卡因相关。
clinical trials in the 1980s evaluated the efficacy of tocainidum for neuropathic pain.
20世纪80年代的临床试验评估了妥卡尼治疗神经性疼痛的功效。
the drug interaction profile suggests caution when combining tocainidum with other sodium channel blockers.
药物相互作用概况表明，妥卡尼与其他钠通道阻滞剂联用时应谨慎。
immediate discontinuation of tocainidum is necessary if symptoms of interstitial pneumonitis appear.
如果出现间质性肺炎症状，必须立即停用妥卡尼。
tocainidum treatment
妥卡尼德治疗
tocainidum therapy
妥卡尼德疗法
tocainidum dosage
妥卡尼德剂量
tocainidum administration
妥卡尼德给药
tocainidum effects
妥卡尼德效果
taking tocainidum
服用妥卡尼德
tocainidum prescription
妥卡尼德处方
tocainidum medication
妥卡尼德药物
tocainidum regimen
妥卡尼德方案
administering tocainidum
使用妥卡尼德
the primary indication for tocainidum is the management of symptomatic ventricular arrhythmias.
盐酸妥卡尼的主要适应症是治疗症状性室性心律失常。
unlike lidocaine, tocainidum can be administered orally for chronic outpatient treatment.
与利多卡因不同，妥卡尼可以口服用于慢性门诊治疗。
physicians rarely prescribe tocainidum due to the potential for severe pulmonary toxicity.
由于可能导致严重的肺毒性，医生很少开具妥卡尼处方。
researchers observed a significant reduction in premature ventricular contractions using tocainidum.
研究人员观察到使用妥卡尼后室性期前收缩显著减少。
patients with bone marrow suppression should avoid using tocainidum if possible.
患有骨髓抑制的患者应尽可能避免使用妥卡尼。
common side effects associated with tocainidum include dizziness, nausea, and tremors.
与妥卡尼���关的常见副作用包括头晕、恶心和震颤。
plasma concentration monitoring is essential to optimize the therapeutic dose of tocainidum.
监测血浆浓度对于优化妥卡尼的治疗剂量至关重要。
tocainidum is a class ib antiarrhythmic agent chemically related to lidocaine.
妥卡尼是一种ib类抗心律失常药，化学结构与利多卡因相关。
clinical trials in the 1980s evaluated the efficacy of tocainidum for neuropathic pain.
20世纪80年代的临床试验评估了妥卡尼治疗神经性疼痛的功效。
the drug interaction profile suggests caution when combining tocainidum with other sodium channel blockers.
药物相互作用概况表明，妥卡尼与其他钠通道阻滞剂联用时应谨慎。
immediate discontinuation of tocainidum is necessary if symptoms of interstitial pneumonitis appear.
如果出现间质性肺炎症状，必须立即停用妥卡尼。
探索常用高频词汇